Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ: AMGN )

328.35 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,564
Open 328.35
Bid (Size) 323.30 (2)
Ask (Size) 324.00 (1)
Prev. Close 328.35
Today's Range 328.35 - 328.35
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga

Performance

YTD
+10.41%
+10.41%
1 Month
-1.23%
-1.23%
3 Month
-0.55%
-0.55%
6 Month
+23.67%
+23.67%
1 Year
+14.46%
+14.46%

More News

Read More
2 Top Dividend Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Via Benzinga
Topics Stocks
Exposures US Equities
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
Via The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
Via The Motley Fool
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Should You Buy the Dip on This Top Growth Stock?
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AskSlim Market Week - Friday, Sep. 27
Via Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Via Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
Via The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.